Potential new approach to the treatment of multiple sclerosis

March 5, 2018, Universitaet Mainz
EGLF7 retains immune cells in the perivascular space in MS lesions. Credit: Catherine Larochelle, Timo Uphaus, Frauke Zipp

A prospective new method of treating patients with multiple sclerosis has been proposed by researchers of the Mainz University Medical Center working in cooperation with researchers of the University of Montreal. In model trials and experiments employing human endothelial cells, they discovered that the EGFL7 protein hinders the migration of immune cells into the central nervous system by stabilizing the blood-brain barrier. These findings have recently been published in Nature Communications.

The autoimmune disease (MS) is one of the most common disorders that cause disabilities in young adults in industrialized countries. In MS, the body's own immune system attacks the central nervous system (CNS). Immune (T cells) cross the , i.e., the physiological barrier between the blood circulatory system and the CNS, enter the brain, and damage the protective covering of the nerve fibers, the myelin layer. This results in the degeneration and loss of function of and leads to neurological disability-related symptoms.

The primary aim of MS research is to develop new treatments that will prevent this pathological process. The researchers chose a completely innovative pathophysiological-based approach as EGFL7 had not previously been considered of relevance to MS research. However, it has been shown, for example in the case of breast cancer, that EGFL7 does have an influence on the migration of into tumor tissue. Since the migration of immune cells into the brain plays a significant role in MS, the researchers decided to investigate this protein and whether it could also have an effect on the autoimmune disorder. Notably, on the basis of their results they were able to demonstrate a possible new approach to successfully treat MS.

The researchers discovered that CNS inflammation was accompanied by an increased release of EGFL7. Immune cells subsequently bind to EGFL7, in a sense being taken prisoner so that they are prevented from crossing into the CNS. EGFL7 is released by the endothelial cells of the blood-brain barrier and causes immune cells to be retained in the perivascular space. In their model trials, the researchers next found that exposure to EGLF7 makes the blood-brain barrier less permeable. In the presence of this more effective barrier, the passage of immune cells into the CNS was reduced. This counteracted the corresponding pathological mechanisms and thus led to improvements in clinical symptoms.

Furthermore, the researchers were able to confirm their experimental findings in a human blood-brain barrier model, where there was also decreased migration of immune cells in isolated . They now conclude that it might be possible in principle to take advantage of the way that EGFL7 inhibits the migration of immune cells into the CNS and enhances the impenetrability of the blood-brain for the treatment of multiple sclerosis.

Explore further: How rogue immune cells cross the blood-brain barrier to cause multiple sclerosis

More information: Catherine Larochelle et al. EGFL7 reduces CNS inflammation in mouse, Nature Communications (2018). DOI: 10.1038/s41467-018-03186-z

Related Stories

How rogue immune cells cross the blood-brain barrier to cause multiple sclerosis

November 21, 2017
Drug designers working on therapeutics against multiple sclerosis should focus on blocking two distinct ways rogue immune cells attack healthy neurons, according to a new study in the journal Cell Reports.

Cellular self-digestion process triggers autoimmune disease

December 13, 2017
Autophagy refers to a fundamental recycling process of cells that occurs in yeast, fungi, plants, as well as animals and humans. This process allows cells to degrade their own components and thus activate energy resources ...

Cancer drug a possible treatment for multiple sclerosis

February 21, 2013
(Medical Xpress)—A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE. The discovery, ...

A breakthrough in pinpointing protective mechanisms in Multiple Sclerosis

December 2, 2011
In an article published in the prestigious journal Science, a team of researchers led by Dr Alexander Prat and postgraduate fellow Jorge Alvarez at the University of Montreal Hospital Research Centre (CRCHUM) sheds light ...

Identifying the dangers of chronic stress on multiple sclerosis

February 6, 2018
New research reveals how chronic stress and tiny brain inflammations cause fatal gut failure in a multiple sclerosis mouse model.

Researchers report novel complementary effects of estrogen treatment in multiple sclerosis

December 28, 2017
A study by UCLA researchers reveals the cellular basis for how the hormone estrogen protects against damage to the central nervous system in people with multiple sclerosis (MS). The researchers found that estrogen treatment ...

Recommended for you

Perinatal hypoxia associated with long-term cerebellar learning deficits and Purkinje cell misfiring

August 18, 2018
Oxygen deprivation associated with preterm birth leaves telltale signs on the brains of newborns in the form of alterations to cerebellar white matter at the cellular and the physiological levels. Now, an experimental model ...

CRISPR technology targets mood-boosting receptors in brain

August 17, 2018
An estimated 13 percent of Americans take antidepressant drugs for depression, anxiety, chronic pain or sleep problems. For the 14 million Americans who have clinical depression, roughly one third don't find relief with antidepressants.

People are more honest when using a foreign tongue, research finds

August 17, 2018
New UChicago-led research suggests that someone who speaks in a foreign language is probably more credible than the average native speaker.

Critical role of DHA on foetal brain development revealed

August 17, 2018
Duke-NUS researchers have found evidence that a natural form of Docosahexaenoic Acid (DHA) made by the liver called Lyso-Phosphatidyl-Choline (LPC-DHA), is critical for normal foetal and infant brain development, and that ...

Automated detection of focal epileptic seizures in a sentinel area of the human brain

August 17, 2018
Patients with focal epilepsy that does not respond to medications badly need alternative treatments.

Men and women show surprising differences in seeing motion

August 16, 2018
Researchers reporting in the journal Current Biology on August 16 have found an unexpected difference between men and women. On average, their studies show, men pick up on visual motion significantly faster than women do.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Anonym491930
1 / 5 (1) Mar 15, 2018


RICO
My first symptom of MS was when I was 16 years old. The main symptom was about 30 years later when I went blind. I had many symptoms through my life, but wasn't tested for MS until the blindness. I've had problems with fatigue and balance. Thank God for leading me to BEST HEALTH HERBAL CENTRE, please don't ignore this post is real. Best Health Herbal Centre MS herbal remedy cured me totally within 6 weeks of usage only. No side effect, it works like a miracle, please viewers out there that have any deadly disease, please don't fail contact Best Health Herbal Centre

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.